Optimal timing for activation of sigma 1 receptor in the Pde6b


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
01 2021
Historique:
received: 09 10 2020
revised: 24 11 2020
accepted: 07 12 2020
pubmed: 15 12 2020
medline: 27 4 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Sigma 1 Receptor (Sig1R), a pluripotent modulator of cell survival, is a promising target for treatment of retinal degenerative diseases. Previously, we reported that administration of the high-affinity, high-specificity Sig1R ligand (+)-pentazocine, ((+)-PTZ) beginning at post-natal day 14 (P14) and continuing every other day improves visual acuity and delays loss of photoreceptor cells (PRCs) in the Pde6βrd10/J (rd10) mouse model of retinitis pigmentosa. Whether administration of (+)-PTZ, at time points concomitant with (P18) or following (P21, P24) onset of PRC death, would prove neuroprotective was investigated in this study. Rd10 mice were administered (+)-PTZ intraperitoneally [0.5 mg/kg], starting at either P14, P18, P21 or P24. Injections continued every other day through P42. Visual acuity was assessed using the optokinetic tracking response (OKR). Rd10 mice treated with (+)-PTZ beginning at P14 retained visual acuity for the duration of the study (~0.33 c/d at P21, ~0.38 c/d at P28, ~0.32 c/d at P35, ~0.32 c/d at P42), whereas mice injected beginning at P18, P21, P24 showed a decline in acuity when tested at P35 and P42. Their acuity was only slightly better than rd10-non-treated mice. Electrophysiologic function was assessed using scotopic and photopic electroretinography (ERG) to assess rod and cone function, respectively. Photopic a- and b-wave amplitudes were significantly greater in rd10 mice treated with (+)-PTZ beginning at P14 compared with non-treated mice and those in the later-onset (+)-PTZ injection groups. Retinal architecture was visualized in living mice using spectral domain-optical coherence tomography (SD-OCT) allowing measurement of the total retinal thickness, the inner retina and the outer retina (the area most affected in rd10 mice). The outer retina measured ~35 μm in rd10 mice treated with (+)-PTZ beginning at P14, which was significantly greater than mice in the later-onset (+)-PTZ injection groups (~25 μm) and non-treated rd10 mice (~25 μm). Following the visual function studies performed in the living mice, eyes were harvested at P42 for histologic analysis. While the inner retina was largely intact in all (+)-PTZ-injection groups, there was a marked reduction in the outer retina of non-treated rd10 mice (e.g. in the outer nuclear layer there were ~10 PRCs/100 μm retinal length). The rd10 mice treated with (+)-PTZ beginning at P14 had ~20 PRCs/100 μm retinal length, whereas the mice in groups beginning P18, P21 and P24 had ~16 PRCs/100 μm retinal length. In conclusion, the data indicate that delaying (+)-PTZ injection past the onset of PRC death in rd10 mice - even by a few days - can negatively impact the long-term preservation of retinal function. Our findings suggest that optimizing the administration of Sig1R ligands is critical for retinal neuroprotection.

Identifiants

pubmed: 33310057
pii: S0014-4835(20)30655-2
doi: 10.1016/j.exer.2020.108397
pmc: PMC7808329
mid: NIHMS1657010
pii:
doi:

Substances chimiques

Receptors, sigma 0
Cyclic Nucleotide Phosphodiesterases, Type 6 EC 3.1.4.35
Pde6b protein, mouse EC 3.1.4.35

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108397

Subventions

Organisme : NEI NIH HHS
ID : P30 EY031631
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023242
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028103
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY028671
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Références

Prog Retin Eye Res. 2018 Jan;62:24-37
pubmed: 28962928
Free Radic Biol Med. 2015 Sep;86:25-36
pubmed: 25920363
Vision Res. 2002 Feb;42(4):517-25
pubmed: 11853768
Prog Retin Eye Res. 2018 Nov;67:130-149
pubmed: 30075336
J Mol Neurosci. 2020 Jun;70(6):968-980
pubmed: 32072483
Prog Retin Eye Res. 2015 Sep;48:62-81
pubmed: 26113212
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2770-81
pubmed: 27206247
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4154-61
pubmed: 18469181
Vision Res. 2007 Mar;47(5):624-33
pubmed: 17267005
Lakartidningen. 2019 Dec 2;116:
pubmed: 31794048
J Pharmacol Sci. 2015 Jan;127(1):17-29
pubmed: 25704014
Eur J Neurosci. 2013 Jun;37(11):1853-62
pubmed: 23551187
Cutan Ocul Toxicol. 2020 Mar;39(1):36-42
pubmed: 31648555
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4545-4558
pubmed: 28877319
Adv Exp Med Biol. 2019;1185:457-462
pubmed: 31884654
J Comp Neurol. 2007 Jan 10;500(2):222-38
pubmed: 17111372
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94
pubmed: 17898305
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
pubmed: 15557474
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):3221-3235
pubmed: 31335948
J Neurochem. 2019 Jan;148(2):307-318
pubmed: 30315650
J Neurochem. 2011 Sep;118(5):915-27
pubmed: 21689103
Sci Rep. 2015 Jun 02;5:10689
pubmed: 26033680
Cell Physiol Biochem. 2020 Feb 7;54(1):142-159
pubmed: 32028545
J Biol Chem. 2011 Mar 25;286(12):10551-67
pubmed: 21224384
Exp Eye Res. 2015 Mar;132:64-72
pubmed: 25616094
ACS Chem Neurosci. 2020 Aug 5;11(15):2173-2191
pubmed: 32589402
Free Radic Biol Med. 2019 Apr;134:604-616
pubmed: 30743048
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):5
pubmed: 32150247
Redox Biol. 2019 Jun;24:101199
pubmed: 31026769
Stem Cell Res Ther. 2020 Mar 4;11(1):98
pubmed: 32131893
Trends Pharmacol Sci. 2016 Apr;37(4):262-278
pubmed: 26869505
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):86-95
pubmed: 11687279
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5576-82
pubmed: 17122151
Eur J Pharmacol. 2006 Apr 24;536(1-2):200-3
pubmed: 16580663
J Ophthalmol. 2017;2017:9620876
pubmed: 28573047
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4397-4407
pubmed: 31639826
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3764-72
pubmed: 27298364
Exp Eye Res. 2013 Feb;107:21-31
pubmed: 23183135

Auteurs

Jing Wang (J)

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.

Haiyan Xiao (H)

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.

Shannon Barwick (S)

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.

Yutao Liu (Y)

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States.

Sylvia B Smith (SB)

Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States; James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States; Department of Ophthalmology, Medical College of Georgia at Augusta University, Augusta, GA, United States. Electronic address: sbsmith@augusta.edu.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH